Comparison of a Phytotherapeutic Agent (Permixon) with an -Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study

By Debruyne F.   Koch G.   Boyle P.   Da Silva F.C.   Gillenwater J.G.   Hamdy F.C.   Perrin P.   Teillac P.   Vela-Navarrete R.   Raynaud J.-P.   For the members of the PERMAL Study Group  

European Urology, Vol. 41, Iss. 5, 2002-05 ,pp. : 497-507

Elsevier

Access to resources Recommend Favorite

Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia

By Boyle P.   Robertson C.   Lowe F.   Roehrborn C.  

Urology, Vol. 55, Iss. 4, 2000-04 ,pp. : 533-539

Elsevier

Access to resources Recommend Favorite

Long-term treatment and prognostic factors of α₁-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: A pilot study comparing naftopidil and tamsulosin hydrochloride

By Kawachi Yoshio   Sakurai Toru   Sugimura Sosuke   Iwata Shinji   Noto Kensho   Honda Shin-Ichi   Maruyama Osamu  

Scandinavian Journal of Urology and Nephrology, Vol. 44, Iss. 1, 2010-02 ,pp. : 38-45

Informa Healthcare

Access to resources Recommend Favorite

Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic Hyperplasia - a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH)

By Lepor H.  

Urology, Vol. 51, Iss. 6, 1998-06 ,pp. : 892-900

Elsevier

Access to resources Recommend Favorite

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results

By Lukacs B.   Leplegrave ge A.   Thibault P.   Jardin A.  

Urology, Vol. 48, Iss. 5, 1996-11 ,pp. : 731-740

Elsevier

Access to resources Recommend Favorite